Alumis(ALMS)
SOUTH SAN FRANCISCO, CABiotechnology
Focus: Alumis is a publicly traded biotechnology company focused on autoimmune treatments, specifically targeting immunology indications like psoriasis and uveitis. Founded in 2010 and headquartered in South San Francisco, the company operates as a clinical-stage biotech with an unusually high R&D intensity.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
17
Should You Work at Alumis?
AI assessmentBest suited for early-to-mid career professionals seeking high-growth biotech exposure in immunology with near-term clinical catalysts, provided they accept pre-commercial risk and potential restructuring if Phase 3 programs underperform.
Why Work Here
- Heavy pipeline investment: 13 active clinical trials across Phase 1-3 with two Phase 3 programs (envudeucitinib and ESK-001 for psoriasis) approaching near-term catalysts.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$24M
Pipeline & Clinical Trials
ESK-001
Hepatic ImpairmentClinical Trials (1)
NCT06952634An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
Phase 1Help build intelligence for Alumis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.